Abortion is termination of pregnancy, which can be done by using a medicine or surgery to remove the embryo or fetus as well as placenta from the uterus. Furthermore, mifepristone and misoprostol are abortion medicines that are a safe and effective way to terminate pregnancy. Moreover, progesterone hormone helps in normally pregnancy growth so that to block the effect of progesterone hormone, mifepristone abortion medicine is used. When the progesterone hormones are blocked, the lining of uterus breaks down and pregnancy gets terminated. Also, after taking mifepristone, doctor recommends to take second abortion medicine called misoprostol, which causes bleeding and cramping to empty the uterus. If the patient does not have bleeding within 24 hours after taking misoprostol, the patients should consult a doctor. The patient can take abortion medicine up to 70 days (10 week) after the first day of last mensuration. If it has been more than 70 days since the first day of last mensuration, doctor recommends to go for surgery to terminate the pregnancy. Mifepristone is also marketed under the name, Mifeprex, Korlym, and RU486.

Global Abortion Drugs Market: Drivers

The abortion drugs market is expected to experience significant growth over the forecast period due to increasing abortion cases among women, globally. For instance, according to the Centers for Disease Control and Prevention, 623,471 abortion cases were reported in 2016. According to the same source, rate of abortion was 11.6 per 1,000 individual women who are in the age group of 15 to 44 years in 2016.

Furthermore, in 2016, new label for mifepristone medicine was approved by the U.S. Food and Drug Administration (FDA). Moreover, the U.S FDA approval of new label for mifepristone assures safety of medicine for all women.

Global Abortion Drugs Market: Restraints

However, side effects associated with the mifepristone drug for termination of pregnancy such as fever higher than 100.4 degree for longer than four hours, vomiting, nausea, diarrhea, and severe pelvic pain are major factors that restrain the global abortion drugs market growth.

Moreover, high cost associated with the mifepristone drug is another factor hampering the global abortion drugs market growth. For instance, cost of mifepristone drug is US$ 83.33 for every 200mg tablet in the U.S.

Furthermore, on March 24, 2020, Texas announced abortion as non-essential procedure to keep the valuable medical resources for treating COVID-19 patients only. it is mentioned that violators can be fined or jailed. As a result, the demand for abortion medicine is expected to decrease in the U.S.

Global Abortion Drugs Market: Regional Analysis

North America is expected to hold the largest market share in the global abortion drugs market, owing to increasing approval of drugs for the termination of pregnancy, which is driving the global abortion drugs market growth. For instance, in April 2019, the U.S Food and Drug Administration (FDA) approved GenBioPro, Inc.’s generic Mifeprex medicine, which is used for the termination of intrauterine pregnancy through 70 days gestation. This approval reflects FDA’s determination that GenBioPro’s product, Mifepristone Tablets, 200 mg, is therapeutically equivalent to Mifeprex as well as can be safely substituted for Mifeprex.

Global Abortion Drugs Market: Key Players

Key players operating in the global abortion drugs market include Corcept Therapeutics Inc., Danco Laboratories LLC, GenBioPro, Inc., Sandoz Inc, Yung Shin Pharmaceutical Industrial Co Ltd, Amneal Pharmaceuticals, Actavis Laboratories Fl Inc., Novel Laboratories Inc., and G.D. Searle, LLC.

Market Taxonomy:

On the basis of drug, the global abortion drugs market is segmented into:

Mifepristone
Misoprostol

On the basis of distribution channel, the global abortion drugs market is segmented into:

Hospital pharmacies
Retail Pharmacies
Online Pharmacies

On the basis of region, the global abortion drugs market is segmented into:

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

About Author

Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.

Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.